IMVT-1401, a thyroid eye disease treatment candidate, showed a 65% improvement in IgG levels in a phase 2a proof-of-concept study, Immunovant announced in a press release.
The multicenter, open-label, single-arm ASCEND GO-1 clinical trial included seven adult patients who received two weekly 680 mg subcutaneous doses of IMVT-1401 followed by four weekly 340 mg subcutaneous doses, the release said.
Four of the seven patients had an improvement of 2 points or more in clinical activity score. Six of the seven participants had baseline diplopia, and four of them experienced improvement.
“These
Uncategorized